The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy. Data of human epidemiological studies have not been published so far. Pair analysis of cases with congenital anomalies and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included 38,151 pregnant women who delivered newborn infants without any congenital defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27%) and 98 (0.26%) pregnant women were treated with natamycin in the case and the control group, respectively (crude OR 1.1 with 95% CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period for most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95% CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in the control newborn infants born to mothers who have had natamycin treatment as compared to the data of control newborn infants without this treatment (adjusted p=0.01), though the mean gestational age was shorter. From this study we may conclude that treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk for the fetus.
|Translated title of the contribution||A case-control teratological study of vaginal natamycin treatment during pregnancy|
|Number of pages||6|
|Journal||Magyar Noorvosok Lapja|
|Publication status||Published - Aug 13 2004|
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynaecology